BD (Becton, Dickinson and Company) has appointed Shawn Bevec as Senior Vice President of Investor Relations, effective January 20, 2026. In this role, Bevec will spearhead all investor communications, presenting BD’s strategic initiatives and performance metrics to the financial community. He will report directly to Interim CFO Vitor Roque until a permanent finance leader is appointed. Bevec joins BD from Quest Diagnostics, where he served as Vice President of Investor Relations and led earnings presentations and capital markets engagement. His prior experience includes equity research coverage of health care services and medical devices at Deutsche Bank and Susquehanna International Group, as well as research and development roles at Pfizer and Johnson & Johnson. Bevec holds a B.S. in Chemistry from the University of Arizona and an MBA in General Management from NYU’s Stern School of Business. Investors will watch how his expertise shapes BD’s messaging around growth drivers, shareholder-value initiatives and long-term financial targets.

BD announced a $110 million capital investment to expand its BD Neopak™ Glass Prefillable Syringe platform at its Columbus, Nebraska site, creating approximately 120 new jobs. Of the total, $100 million will establish production lines for 1 mL and 2.25 mL glass prefillable syringes—designed for high-viscosity biologics and GLP-1 therapies—and support integration with autoinjectors. An additional $10 million will upgrade cannula manufacturing capabilities. Supply from the new lines is expected to begin in mid-2026. This investment builds on a prior $35 million expansion in Columbus that added 50 jobs for prefilled flush syringes, and contributes to BD’s broader plan to invest over $2.5 billion in U.S. manufacturing capacity over the next five years. By localizing production, BD aims to strengthen pharmaceutical supply chain resilience, accelerate time to market for advanced injectable therapies and reinforce its leadership in biologics drug delivery.